


医药智库使用培训 – Genmab

- ❑ [服务团队](#) | [资源中心](#) | [当前订阅](#)
- ❑ [登录使用](#) | [Ask the Analyst](#)
- ❑ [各库基本概要 & 使用辅助](#) 【Global License Only】 :
 - [Citeline](#) – 全球R&D综合数据【创新药、临床试验、研究者/中心、患者RWD】
 - [Biomedtracker](#) – 管线追踪、获批预测、商业资讯、调研报告
 - [Pharmapremia](#) – 历史研发统计：研发概率、获批概率、研发用时
 - [Datamonitor Healthcare](#) – 疾病格局分析、10-20年市场预测、KOL专访
 - [News & Insights](#) – 全球业界资讯及见解【商业/研发、监管/立法】
- ❑ [Live Demo: Citeline/Biomedtracker/Datamonitor](#)





服务团队 & 资源中心


Global **Lucia Villaverde (us)** *主要联系人
Account Manager
lucia.villaverde@citeline.com

Renee Szyfer (us) *主要联系人
Client Success Manager
renee.szyfer@citeline.com


Global Client Services
clientservices@citeline.com

Citeline/Genmab 资源中心

- ✓ 登录链接
- ✓ 联系方式
- ✓ 分析师咨询服务 **【Ask the Analyst】**
- ✓ 使用培训支持
- ✓ 调研报告下载



Citeline Solutions



Commercial Success

Assess Risk, Predict Future Impact & Benchmark

BIOMEDTRACKER
CITELINE COMMERCIAL
Real-time tracking of events, catalysts, and deals analysis

DATAMONITOR HEALTHCARE
CITELINE COMMERCIAL
Market assessments, disease analysis, epidemiology and forecasts

PHARMAPREMIA
CITELINE COMMERCIAL
Probability of success / likelihood of approval

News & Insight

SCRIP
CITELINE COMMERCIAL
Commercial activity & market movements

IN VIVO
CITELINE COMMERCIAL
Strategic industry analysis & market growth strategies

HBW INSIGHT
CITELINE COMMERCIAL
OTC, dietary supplements and cosmetic markets

GENERICS BULLETIN
CITELINE COMMERCIAL
Generics, biosimilars and value-added medicines industries

Medtech

MEDDEVICETRACKER
CITELINE COMMERCIAL
Events, catalysts, deals and market forecasts

MEDTECH INSIGHT
CITELINE COMMERCIAL
Commercial, Regulatory and policy perspective

Clinical Planning

Benchmark Optimize Enrollment & Select Sites Find, Educate, Engage, & Enroll Participants

PHARMAPROJECTS
CITELINE CLINICAL
Preclinical to launch pipeline intelligence—drugs, companies, development statuses, targets, MOAs and more

TRIALTROVE
CITELINE CLINICAL
Clinical trial intelligence—trial designs, endpoints & trial timing data and visualizations

SITETROVE
CITELINE CLINICAL
Site and investigator intelligence
Contact information, trial experience and specialties

Patient Data and Diversity
US patient diagnosis & demographic data. Identify which investigators have access to relevant patients and incorporate into your diversity planning

Patient Engagement & Recruitment

CITELINE CONNECT
CITELINE CLINICAL
Find potential trial participants with:

- Recruitment marketplace with a network of 100+ partners
- Direct to patient advertising
- Real world data to locate HCPs with known patient pools
- Direct to HCP advertising

Educate potential trial participants with:

- Enterprise trial portfolio website
- Trial or disease-specific websites
- Geofenced translations

Engage potential trial participants with:

- Chatbot applications / call center
- Community portals
- Advanced trial matching
- Medical record sync
- Patient visit scheduler

Enroll potential trial participants with:

- Enrollment hub with pre-screener technology and analytics
- Referral management services

Regulatory & Compliance

Regulatory Strategy Report & Disclose

PINK SHEET
CITELINE REGULATORY
Regulatory and compliance journalism, analysis and insights

TRIALSCOPE INTELLIGENCE
Regulatory Intelligence Tracking
Detailed knowledge, research and tracking of global regulatory requirements required for CTTD compliance – all in one place

TRIALSCOPE DISCLOSE
CITELINE REGULATORY
End-to-end disclosure management and compliance SaaS Platform

Clinical trial disclosure services, from advisory to technical writing including:

- Protocol Registration
- Results Postings
- Plain Language Summaries
- Redactions

TRIALSCOPE ATLAS
CITELINE REGULATORY
Global disclosure compliance tracking platform



当前订阅范围 [Global Access Only]

Global R&D Intelligence

【数据整理】

PHARMAPROJECTS
CITELINE CLINICAL

TRIALTROVE
CITELINE CLINICAL

SITETROVE
CITELINE CLINICAL

Commercial Intelligence

【分析与预测】

BIOMEDTRACKER
CITELINE COMMERCIAL

PHARMAPREMIA
CITELINE COMMERCIAL

DATAMONITOR HEALTHCARE
CITELINE COMMERCIAL

Industry Updates

【新闻与见解】

SCRIP
CITELINE COMMERCIAL

PINK SHEET
CITELINE REGULATORY

如何登录使用?

- ❑ **Single-Sign-On (SSO) 登录方式**
【通过公司邮箱统一登录；无须密码】
- ❑ **连接Genmab网络即可使用**



注：若需辅助请联系[我们](#)

1

浏览数据库网址
【资源中心】

NEWS & INSIGHTS

Scrip >>>
Pink Sheet >>>
In Vivo >>>

Generics Bulletin >>>
HBW Insight >>>
Medtech Insight >>>

Citeline >>>

Pharmaprojects >>>
Trialtrove >>>
Sitetrove >>>

➡

BIOMEDTRACKER
CITELINE COMMERCIAL

PHARMAPREMIA
CITELINE COMMERCIAL

DATAMONITOR HEALTHCARE
CITELINE COMMERCIAL

2

输入公司邮箱
【无须密码】

Welcome to Citeline Clinical Intelligence

Log in with your corporate email to continue.

Email address

Continue

Don't have an account? [Sign up here](#)

3

自动认证登录

Redirecting to your authentication provider based on the username provided

Cancel

➡

INTELLIGENCE

419,679 trials

View related: Investigators (549,385) | Organizations (294,536) | Drugs (100,112)

Filter categories

Drugs Tested

Details

Therapeutic Class

Mechanism Of Action

Target

Primary Drug Status

Trial

Details

Trial Title

Protocol/Trial ID

Trial Phase

Trial Status

Trial ID

Trial Title	Protocol/Trial ID	Trial Phase	Trial Status	Countries	Sponsor
☐ Short-term Protection for COVID-19 by Oral Polio Vaccine	18CT201404281374MR1 TrialtroveID-375504	III	Closed	Iran	(Other) Cooperati...
☐ Evaluation of the Effectiveness and Safety of the BNT162 COVID-19 Vaccine in the Vaccination Campaign Among the Health Workers of Fundacion Policlinica Universitaria Argentina General SANCES	3973 NCT02774418 TrialtroveID-402805	IV	Completed	Italy	(Other) Hospital/A...
☐ A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of the BNT162 COVID-19 Vaccine	CTR202003009 CNSL2000001-001 NCT02930476	III	Planned	China	China National P... China National P... China National P...

需要检索辅助或独家见解? Ask-the-Analyst!

- ✓ 无额外收费
- ✓ 无提问次数限制
- ✓ 24小时回复 (工作日)
- ✓ 每提问4小时调研时间

[Back To Homepage](#)



Past Inquires...

BIOMEDTRACKER
CITELINE COMMERCIAL

PHARMAPREMIA
CITELINE COMMERCIAL

DATAMONITOR HEALTHCARE
CITELINE COMMERCIAL



- ❖ “What’s the historic likelihood of approval benchmark for Oncology drugs in phase II & III, how’s the current pipeline looking, and what drugs are doing well and why?”
- ❖ “I would like to review all key trial data releases along with Biomedtracker’s opinion within solid cancers from this year’s ASCO & ESMO, it will be nice if there’s an easy way to search for all relevant events but also locating the abstracts/posters if available?”
- ❖ “Please provide a list of acquisition/alliance deals occurred in the last 3 years within the field of Oncology and PD-1/PD-L1? I’d like to know the deal value, companies, financial terms, and perhaps the actual agreement if available?”
- ❖ “Can you provide the historic sales data of the top-50 best-selling drugs between 2015-2019 along with the latest consensus forecast?”

- ❖ “Good morning, can you please build me a search strategy to quickly look for the latest landscape of ADC drugs’ pipeline development within Asia? I will need to know the general overview in indications and companies in each key Asian markets, and ideally to further narrow down to the ones originated by local companies plus the ones yet to have any partnership agreements with foreign/global firms?”
- ❖ “Is it possible to set up multiple alerts on multiple companies’ pipeline within Immuno-Oncology, but only receive a single email on daily basis with all updates included?”
- ❖ “I need a quick overview on Rare Disease competitive landscape including active pipeline, companies, clinical trials along with associated investigators & sites, and display everything via dashboard/charts plus the option for Excel export, is this something possible in an easy manner?”
- ❖ “I’m currently working in feasibility assessment and require clinical trials’ benchmark data over average accrual/sites/enrollment rate of all industry-sponsored multinational AML trials, by phase, that were either completed or enrolled, and the average pts/site/month calculation by country if possible?”

注：各库右上角均设有Ask the Analyst提问按钮

The screenshot shows the Citeline Intelligence Clinical interface. At the top, there's a navigation bar with 'Intelligence CITELINE CLINICAL', 'Trialtrove', 'Sitetrove', and 'Pharmaprojects'. A search bar is present. Below the navigation bar, there's a section for 'Filter categories' and a list of trials. A red box highlights the 'Ask the Analyst' button in the top right corner. A red arrow points to this button. Below the button, a modal form titled 'Ask the Analyst' is displayed. The form contains the following text: 'Your questions answered by our experts', 'Ask the Analyst is a complimentary service that is included in your Pharmaprojects subscription.', 'Citeline's therapy and product experts will assist you with questions about specific clinical trials within the scope of coverage, building effective search strategies and other creative solutions to meet your information needs. Up to three hours of analyst support is available per request.', 'Please take advantage of this valuable service and fill in the details of your request below. You will receive an automated acknowledgement, and a Citeline analyst will respond to you directly by the next business day.', and a text input field labeled 'Describe the information you need'. A 'Send' button is at the bottom right of the form.

NEWS
&
INSIGHTS

Scrip
Pink Sheet
In Vivo

Generics Bulletin
HBW Insight
Medtech Insight

- ❖ “Can you provide me with the latest updates of the US BIOSECURE act?”
- ❖ “Do you track down regulatory guidance from major regulators?”
- ❖ “Good morning, the new CTIS system in Europe will be going online next month, can you provide a summary of some of the key changes compared to the old online trial registry?”

使用辅助资源

使用辅助资源

【教程视频、功能更新、报告下载】

Chinese Training Materials

Pharmaprojects

【使用教程视频】Pharmaprojects基本综述

实用检索：Novel Target（持续更新）

【功能更新】Customizable Dashboard - 2023年6月

【功能更新】Rare Disease - 2022年2月

Sitetrove

【使用教程视频】Sitetrove研究者信息综述

【使用教程视频】Sitetrove临床机构信息综述

【功能更新】Diversity Heatmap & Dashboard - 2023年11月

【功能更新】Diversity Module - 2023年6月

Trialtrove

【使用教程视频】Trialtrove基本综述

实用检索：全球各大医学年会临床披露（持续更新）

【功能更新】Customizable Dashboard - 2023年6月

【功能更新】Single vs Multinational Trials - 2023年3月

【功能更新】Decentralized Trials - 2022年12月

【功能更新】Rare Disease - 2022年2月

[See all 8 articles](#)

Citeline Whitepapers (Chinese)

2024年医药研发趋势年度分析

2022年临床试验综述

2023年医药研发趋势年度分析

2021年临床试验综述：后疫情时代是否已进入新常态？

查看更多使用辅助资源？请线上查阅[Help Center](#)

辅助资讯

Pharmaprojects

- ❖ [涵盖范围说明](#)
- ❖ [用词释义](#)
- ❖ [Therapeutic Class分类释义](#)
- ❖ [用户常见答疑](#)
- ❖ [其他辅助](#)

Trialtrove

- ❖ [涵盖范围说明](#)
- ❖ [用词释义](#)
- ❖ [常见临床检索提示](#)
- ❖ [用户常见答疑](#)
- ❖ [其他辅助](#)


Sitetrove

- ❖ [涵盖范围说明](#)
- ❖ [用词释义](#)
- ❖ [常见检索提示](#)
- ❖ [用户常见答疑](#)
- ❖ [Patient Proximity答疑](#)
- ❖ [其他辅助](#)

每月公开培训

【各时区每月一场或以上场次；涵盖英语、中文、日语场次】

注：若需定制化培训，请联系我们进行安排



- 涵盖范围：管线 – 美欧日市场为主；公司/交易/融资 – 全球
- 更新频率：每日【非英语来源须3-5天更新】
- 信息来源：公开信息【如：各地监管网站、公司官网/财报、会议/文献】

药品开发追踪【历史事件 vs. 未来计划】

(如：研发、临床、监管、商业)

药品获批概率预测【详解】

(LoA – 人为点评 vs. PoA – 大数据分析)

综合商业资讯

(如：公司财政状况及管理层名单、全球交易事件、药品历史销量/投行预测、药物专利)

专题报告

(如：医学会议综述、季度前瞻、专题调研报告)

FDA咨询委员会投票历史



Clinical Trial Analysis	Drug	Lead Company	Partner	Target	Phase	Est. Approval Date	Likelihood of Approval	Peak U.S. Revenue (M) (2019 Revenue)	Upcoming Catalyst
View Analysis (03/10/20)	Biosimilar Insulin Glargine (Mylan/Biocon)	Mylan N.V. (MYL)	Biocon (BIOS:IN); PISA Pharmaceuticals	Insulin Receptor	BLA	06/20 ↑	92% (3% Above Avg.)		06/01/20 - 06/30/20
View Analysis (07/15/19)	Farxiga	AstraZeneca PLC (AZN)	Ono (4528-JP); Sun Pharma (SUNP:IN); Bristol-Myers Squibb (BMY)	SGLT	NDA	N/A ↓	69% (20% Below Avg.)	\$537.0 (2019 Act.)	
View Analysis (03/20/20)	Jardiance	Boehringer Ingelheim GmbH	Lupin Ltd. (500257-IN); Eli Lilly (LLY)	SGLT	NDA	N/A ↓	48% (12% Below Avg.)		
View Analysis (01/30/20)	LY900014	Eli Lilly & Company (LLY)	N/A	Insulin Receptor	NDA	07/20 10/20 ↑	93% (4% Above Avg.)		Now - 06/30/20
View Analysis (03/11/20)	Zynquista	Lexicon Pharmaceuticals, Inc. (LXRX)	N/A	SGLT	NDA	N/A ↓	64% (25% Below Avg.)		Now - 04/30/20
View Analysis (11/01/18)	Biosimilar Insulin Aspart (Mylan/Biocon)	Mylan N.V. (MYL)	Biocon (BIOS:IN)	Insulin Receptor	III	N/A →	60% (Same As Avg.)		
View Analysis (06/09/19)	SAR341402	Sanofi (SNY)	N/A	Insulin Receptor	III	N/A ↑	63% (3% Above Avg.)		Now - 12/31/20
View Analysis (03/16/20)	Teplizumab	Provention Bio, Inc. (PRVB)	PDL BioPharma (PDLI); MacroGenics (MGNX)	Cluster of Differentiation 3 (CD3)	III	N/A ↑	61% (1% Above Avg.)		04/01/20 - 09/30/20

Analyst Comment	Event Type	Event Date	Event Phase	Change to Likelihood of Approval	Likelihood of Approval
-	Regulatory - Progress Update	03/11/2020	NDA/BLA	0%	64% (22% Below Avg.)
[-]	Regulatory - Response to Formal Dispute Resolution	12/02/2019	NDA/BLA	-5% ↓	64% (22% Below Avg.)
-	Trial Data - Retrospective Analysis	09/17/2019	NDA/BLA	0%	69% (20% Below Avg.)
-	Partnership - Announcement	09/09/2019	NDA/BLA	0%	69% (20% Below Avg.)
-	Trial Data - Published Results	08/01/2019	NDA/BLA	0%	69% (20% Below Avg.)
-	Partnership - Cancellation	07/26/2019	NDA/BLA	0%	69% (20% Below Avg.)
-	Regulatory - Approval (Europe)	04/26/2019	NDA/BLA	0%	69% (20% Below Avg.)
[-]	Regulatory - Complete Response Letter (CRL)	03/22/2019	NDA/BLA	-15% ↓	69% (20% Below Avg.)
-	Regulatory - CHMP (European Panel) Results (Positive)	02/28/2019	NDA/BLA	0%	84% (1% Below Avg.)
[-]	Regulatory - FDA Advisory Panel Meeting	01/17/2019	NDA/BLA	-2% ↓	84% (1% Below Avg.)
[-]	Regulatory - FDA Advisory Panel Update	01/15/2019	NDA/BLA	0%	86% (1% Below Avg.)
[-]	Regulatory - FDA Advisory Panel Brief	01/15/2019	NDA/BLA	1% ↑	85% (1% Below Avg.)
[-]	Regulatory - FDA Advisory Panel Meeting Notification	11/29/2018	NDA/BLA	0%	85% (1% Below Avg.)
[-]	Related Drug - Trial Data	10/04/2018	NDA/BLA	-2% ↓	85% (1% Below Avg.)
-	Trial Data - Updated Results	10/03/2018	NDA/BLA	0%	87% (1% Below Avg.)
[-]	Trial Data - Updated Results	06/24/2018	NDA/BLA	0%	87% (1% Below Avg.)
[-]	Trial Data - Updated Results	06/24/2018	NDA/BLA	0%	87% (1% Below Avg.)
[-]	Trial Data - Updated Results	06/23/2018	NDA/BLA	0%	87% (1% Below Avg.)
-	Regulatory - NDA/BLA Accepted	05/22/2018	NDA/BLA	0%	87% (1% Below Avg.)
-	Regulatory - European Filing Accepted	03/29/2018	NDA/BLA	0%	87% (1% Below Avg.)
-	Regulatory - MAA Submission (Europe)	03/26/2018	NDA/BLA	0%	87% (1% Below Avg.)
-	Regulatory - NDA/BLA Filing	03/26/2018	NDA/BLA	29%	87% (1% Below Avg.)
-	Trial Announcement - Initiation	10/18/2017	III	0%	58% (1% Below Avg.)
-	Trial Announcement	10/15/2017	III	0%	58% (1% Below Avg.)



线上使用教程视频

❑ Product Features:

- ✓ [What is the Likelihood of Approval \(LoA\)?](#)
- ✓ [What is the Probability of Approval \(PoA\)?](#)
- ✓ [Biomedtracker Report Library](#)

❑ General Functionality:

- ✓ [Resources & Email Alerts](#)
- ✓ [Catalyst Search](#)
- ✓ [Events Search](#)
- ✓ [Product Search](#)
- ✓ [Companies Search](#)
- ✓ [Disease Search](#)
- ✓ [Deals Search](#)
- ✓ [Target Search](#)
- ✓ [Patents Content & Email Alert](#)

注：国内可正常播放，视频右小角设有选项开启中文字幕。


辅助资讯

- ❖ [涵盖范围说明](#)
- ❖ [事件类别释义【Events vs. Catalyst】](#)
- ❖ [用户常见答疑](#)
- ❖ [获批概率详解【LoA vs. PoA】](#)

每月公开培训

【各时区每月一场或以上场次；涵盖英语、中文、日语场次】

注：若需定制化培训，请联系我们进行安排



- 涵盖范围：美国管线
- 更新频率：每季度
- 信息来源：公开信息【via Biomedtracker】

□ R&D数据统计【历史、当前】

(如：公司、药物类别、靶点、给药途径等)

□ 研发概率【PoS】VS. 获批概率【LoA】

(进入下阶段平均概率 vs. 平均最终获批概率)


□ 各阶段平均研发耗时

□ 监管筛选功能

(如：Designations, Statues, Skipped Phase II/III, First Indication)

□ 数据图形分析 & 导出

(如：Dashboards, Gantt Chart; Excel Image Download)



使用辅助资源



Methodology详解

- ❖ [统计模型 & 数据来源](#)
- ❖ [数据更新频率](#)


辅助资讯

- ❖ [最新更新一览](#)
- ❖ [用户常见答疑](#)

每月公开培训

【各时区每月一场或以上场次；涵盖英语、中文、日语场次】

注：若需定制化培训，请联系我们进行安排



使用辅助

登录使用



- 涵盖范围：美日欧【英、德、法、意、西】
- 更新频率：每季度、每年【视报告类别而定】
- 信息来源：Primary/Secondary Research

季度性竞争格局分析

(格局综述：历史研发基准、各地标准治疗、研发/交易/监管动态)
(竞争分析：未满足需求、未来趋势、竞品竞争力评估/SWOT分析)

10-20年市场前景预测 via 7MM

(10-20年Epi预测：发病率、患病率)
(10年商业预测：疾病/药品估值规模、份额【Patient-based Forecast模型】)

KOL专访

(涵盖范围：410+不具名专访、涉及各大疾病领域)
(采访焦点：处方习惯、当前挑战、未满足需求、用药见解)

跨国药企动态及分析

(涵盖范围：40+ 欧美日跨国药企)
(关键资讯：近期动态、并购历史、药品销量、财政情况、SWOT分析)

专题调研报告

(如：COVID-19、基因疗法、交易综述、前沿科技、临床研发)



线上使用教程视频

- ☐ [What is Datamonitor Healthcare?](#)
- ☐ [Viewing Patient-Based Forecasts](#)
- ☐ [Viewing Disease Reports](#)
- ☐ [Viewing Company Reports and Analytics](#)


辅助资讯

- ❖ [涵盖范围说明](#)
- ❖ [竞品竞争力对比释义](#)
- ❖ [KOL专访流程释义](#)
- ❖ [流行病学预测模型释义](#)
- ❖ [市场预测模型释义](#)

每月公开培训


【各时区每月一场或以上场次；涵盖英语、中文、日语场次】

注：若需定制化培训，请联系我们进行安排



- 涵盖范围：全球
- 更新频率：实时
- 信息来源：全球在地记者团队

Featured Stories



14 May 2024 | ANALYSIS

Rapid Rise Or Slow Roll: How Long Does It Take To Become A Blockbuster?

By Jessica Merrill and Nancy Pham

Scrip analyzed data on top-selling drugs to see how long it takes to surpass \$1bn in sales and become a blockbuster.

Launches | Commercial | Business Strategies



14 May 2024 | NEWS

Bayer Talks Up Eylea Expansion Plans As Patent Expiry Hits

By Kevin Grogan

CEO Bill Anderson tells Scrip that the switching of patients to the higher dose formulation of the eye disease drug will help secure its future as

Latest News

Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh

5 hours ago

Rapid Rise Or Slow Roll: How Long Does It Take To Become A Blockbuster?

Bayer Talks Up Eylea Expansion Plans As Patent Expiry Hits

Novo Takes

Deals In Bay Area: 5 Targeted

Stock Watch: AstraZeneca

Top 10 Obesity Drugs By Forecast 2028 Sales



Note: Rybelsus not present as Evaluate does not split obesity sales from diabetes sales.

Data Trackers

(Pink Sheet → 各地监管指南、EMA & FDA追踪)



09 May 2024 | INTERVIEWS

BIO Seeks 'Substantial Runway' To Shift Away From China As Momentum For Manufacturing Bill Grows



03 May 2024 | INTERVIEWS

What's The Key To Successful R&D With Artificial Intelligence? 'Bilingual' Scientists



02 May 2024 | INTERVIEWS

ICER Debuts Clinical Trial Diversity Assessment Framework

By Sue Sutter



09 May 2024 | INTERVIEWS

BIO Seeks 'Substantial Runway' To Shift Away From China As Momentum For Manufacturing Bill Grows



03 May 2024 | INTERVIEWS

What's The Key To Successful R&D With Artificial Intelligence? 'Bilingual' Scientists




02 May 2024 | INTERVIEWS

ICER Debuts Clinical Trial Diversity Assessment Framework

By Sue Sutter

Download on the
App Store

GET IT ON
Google Play



全球业界实时动态

(Scrip → 创新药：商业、研发)

(Pink Sheet → 创新药：监管、立法)

事件解读 & 见解

(专家点评：前因后果、潜在影响)

业界权威专访

(如：药企高层、监管/政府官员、业界领袖、医患权益组织)

Data Trackers

(Pink Sheet → 各地监管指南、EMA & FDA追踪)

多媒体内容

(如：手机APP、专家Podcast、Infographics)

使用辅助资源

线上使用教程视频

- ☐ [Email Preferences](#)
- ☐ [Custom Alerts](#)
- ☐ [Ask the Analyst](#)
- ☐ [Search and Results](#)
- ☐ [My View](#)
- ☐ [Regulatory Trackers \(Pink Sheet\)](#)


辅助资讯


- ❖ [My View](#)
- ❖ [Ask the Analyst](#)
- ❖ [User Guide \(PDF\)](#)

每月公开培训


【各时区每月一场或以上场次；涵盖英语、中文、日语场次】

注：若需定制化培训，请联系[我们](#)进行安排





逻辑检索



数据可视化



数据导出



邮件订阅

Pharmaprojects – 全球创新药信息

- ✓ **综合管线格局：**历史趋势/管线规模、当前竞争格局/研发分布【如：技术类别、靶点、作用机制、国家】
- ✓ **药物研发历程：**各地/适应症状态、各期历程、监管事件、加速审批/Designations

Trialtrove – 全球临床试验信息

- ✓ **竞争临床项目：**方案设计、临床终点、时间规划、入组动态、地点选择、数据披露
- ✓ **历史临床对照：**趋势分析、地点/临床终点选择、成败案例对比、临床数据、临床/招募耗时、平均入组率

Sitetrove – 全球研究者、临床中心信息

- ✓ **拥有特定经验的研究者/中心** (所在地、联系方式、从属单位、临床经验)
- ✓ **通过“Investigator Tiering”快速推算出最佳研究者人选**



竞品获批前景

Biomedtracker – 管线追踪、获批前景分析、综合商业资讯、调研报告

- ✓ 竞品研发动态：研发历程、事件综述、未来研发/监管事件
- ✓ 获批前景分析：获批概率对比、关键事件解读、分析师见解
- ✓ 综合商业资讯：公司财政情况/SEC文件、药品历史销量、近期投融资/交易



疾病市场预测

Datamonitor Healthcare – 疾病竞争分析、市场预测、KOL专访

- ✓ 疾病竞争分析：各地标准治疗、未满足需求、未来趋势、药品竞争力对比/SWOT分析
- ✓ 未来市场预测：20年流行病学预测、10年商业前景预测
- ✓ KOL/Payer专访：处方习惯、治疗困难、用药观点